newsfilter
← Latest News
GlobeNewswire·

Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements

– Late-breaking oral presentation of Phase 3 envudeucitinib data in moderate-to-severe plaque psoriasis (PsO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting demonstrating early and robust improvements